Escitalopram-Induced Rash

Prabhakar, Deepak; Sablaban, Ibrahim

doi:10.4088/pcc.18l02302

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one case report, escitalopram was found to cause drug-induced rash and DRESS (drug reaction with eosinophilia and systemic reaction), an adverse drug reaction in other. [ 6 ] The mechanisms underlying cutaneous drug reactions can be either immunological or non–immunological mediated or sometimes unknown. The release of mediators of inflammation from mast cells either directly or through IgE-specific antibodies or production and accumulation of toxic metabolites of drugs result in drug reactions.…”

Section: Discussionmentioning

confidence: 99%

“…Also, this implies that the escitalopram-specific skin reaction had been possibly due to individual variability. [ 6 ] Another probability could be a combination of other drug with propensity to cause skin lesion-like, olanzapine. [ 10 ] The class-dependent effect was found with some SSRIs in literature indicating a switch over to non-SSRI drug when a patient had experienced drug reaction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Escitalopram-Induced Skin Rash

Godi

Singh

2022

Indian Journal of Dermatology

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRI) are the most prescribed antidepressant medications for the treatment of depression and other psychiatric disorders due to their efficacy, tolerability, and safety profile. The dermatological side-effects or cutaneous reactions due to SSRI class of antidepressants is rare. Though there were few case reports of SSRI-induced rash due to fluoxetine, paroxetine, and sertraline, the evidence associated with escitalopram, the highly prescribed antidepressant is comparatively less. The identification and reporting of the drug-related side-effects/adverse drug reactions either serious or non-serious is very important as it will be helpful in understanding, reviewing, and educating the drug-related information before starting medication to the patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Escitalopram-Induced Skin Rash

Godi

Singh

2022

Indian Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…SSRIs have been associated with photosensitivity, spontaneous bruising, pruritus, alopecia, and urticaria [105]. In 2019, a female with a history of asthma and an autoimmune disorder developed an itchy pruritic rash four weeks after starting escitalopram [106]. In another case report, fluoxetine was thought to be the cause of acute urticaria and angioedema in a 23-year-old male [107].…”

Section: Rashmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review

Edinoff

Akuly

Hanna

et al. 2021

Neurology International

188

View full text Add to dashboard Cite

Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, selective serotonin reuptake inhibitors (SSRIs) quickly became a mainstay of treatment for a variety of psychiatric disorders. The primary mechanism of action of SSRIs is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, subsequently increasing serotonin at the postsynaptic membrane in the serotonergic synapse. The six major SSRIs that are marketed in the USA today, fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine, are a group of structurally unrelated molecules that share a similar mechanism of action. While their primary mechanism of action is similar, each SSRI has unique pharmacokinetics, pharmacodynamics, and side effect profile. One of the more controversial adverse effects of SSRIs is the black box warning for increased risk of suicidality in children and young adults aged 18–24. There is a lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression. Adults, who do not have certain risk factors, which could be confounding factors, do not seem to carry this increased risk of suicidality. Ultimately, when prescribing SSRIs to any patient, a risk–benefit analysis must factor in the potential treatment effects, adverse effects, and dangers of the illness to be treated. The aim of this review is to educate clinicians on potential adverse effects of SSRIs.

show abstract